THE US Food and Drug Administration (FDA) has held a Patient-Focused Drug Development meeting as part of its efforts to address the country’s opioid epidemic, drawing on the input of patients living with chronic pain.
The initiative involved both adult and paediatric patients and sought their input on treatments involving medications such as opioids, acetaminophen, non-steroidal anti-inflammatory drugs, antidepressants and other medications, as well as non-pharmacological therapies.
“We want to better understand the challenges or barriers patients face accessing various treatments for pain,” said FDA commissioner Scott Gottlieb.
“We’re hopeful that this meeting will provide valuable insights to inform our opioid policies and advance our efforts to develop better therapies.”
Other recent FDA measures have included a revised blueprint covering core training that opioid drug manufacturers are required to make available to prescribers.